The study further subdivided the gastric cancer patients according to different pathological features, revealing that CA125, AFP, and CEA levels in stage III-IV patients were higher than in stage I-II patients, and that poorly differentiated patients exhibited higher CA125, AFP, and CEA levels than moderately to well-differentiated patients. The gene discussed is AFP; the disease is gastric cancer.